Clinical Trial Update: A Study of Ramucirumab (LY3009806) or Merestinib (LY2801653) in Advanced or Metastatic Biliary Tract Cancer [Phase 2]

View source ↗

Summary

Phase 2 study evaluating ramucirumab or merestinib in advanced or metastatic biliary tract cancer; results were posted in February 2021.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Biliary Tract Cancer

Drugs mentioned

• Merestinib (merestinib)
• Ramucirumab (Cyramza) (ramucirumab)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Biliary Tract Cancer, Metastatic Cancer | Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2021-02-26